Masako Ura

2.0k total citations · 1 hit paper
25 papers, 1.6k citations indexed

About

Masako Ura is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Masako Ura has authored 25 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Masako Ura's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Masako Ura is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Masako Ura collaborates with scholars based in Japan, United States and Switzerland. Masako Ura's co-authors include Hideo Ishitsuka, Masanori Miwa, Nobuo Shimma, Isao UMEDA, Noriaki Sawada, T Ishikawa, M Nishida, Kazushige Mori, Hiroyuki Eda and Yutaka Tanaka and has published in prestigious journals such as International Journal of Cancer, European Journal of Cancer and Pharmaceutical Research.

In The Last Decade

Masako Ura

25 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1998 1.0k citations Masanori Miwa, Masako Ura et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by Masako Ura

Since Specialization

Citations

This map shows the geographic impact of Masako Ura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masako Ura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masako Ura more than expected).

Fields of papers citing papers by Masako Ura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masako Ura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masako Ura. The network helps show where Masako Ura may publish in the future.

Co-authorship network of co-authors of Masako Ura

This figure shows the co-authorship network connecting the top 25 collaborators of Masako Ura. A scholar is included among the top collaborators of Masako Ura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masako Ura. Masako Ura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing surveillance study 2019 ·Japanese Journal of Clinical Oncology ·Motoo Nagane, Yasuko Hayashi, Ayaka Shimizu, Masako Ura, Ryo Nishikawa	11
2	A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts 2009 ·Cancer Chemotherapy and Pharmacology ·Mika Endo, Masanori Miwa, Masako Ura, Hiromi Tanimura, Kenji Taniguchi, Yoko Miyazaki, Jun Ohwada, Masao Tsukazaki, Satoshi Niizuma, Takeshi Murata, (unknown), (unknown), Kotaro Ogawa, (unknown), Shunsuke Nagao, Nobuo Shimma, Hisafumi Yamada‐Okabe	13
3	Involvement of cyclooxygenase‐2 in the tumor site‐dependent production of parathyroid hormone‐related protein in colon 26 carcinoma 2007 ·Cancer Science ·(unknown), (unknown), Toshiaki Tsunenari, Masako Ura, Hideaki Mizuno, (unknown), Etsuro Onuma, Koh Sato, Etsuro Ogata, Hisafumi Yamada‐Okabe	6
4	Design and synthesis of novel prodrugs of 2′-deoxy-2′-methylidenecytidine activated by membrane dipeptidase overexpressed in tumor tissues 2007 ·Bioorganic & Medicinal Chemistry Letters ·Yasunori Kohchi, Kazuo Hattori, Nobuhiro Oikawa, (unknown), Yoshiaki Isshiki, (unknown), (unknown), (unknown), Masanori Miwa, (unknown), Masako Ura, (unknown), Hisafumi Okabe, Hideo Ishitsuka, Nobuo Shimma	5
5	Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine 2003 ·Bioorganic & Medicinal Chemistry Letters ·Kazuo Hattori, Yasunori Kohchi, Nobuhiro Oikawa, (unknown), Masako Ura, Tohru Ishikawa, Masanori Miwa, (unknown), Hiroyuki Eda, Hiromi Tanimura, Akira Kawashima, Ikuo Horii, Hideo Ishitsuka, Nobuo Shimma	22
6	Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889 2003 ·International Journal of Cancer ·Mika Endo, Masanori Miwa, Hiroyuki Eda, Masako Ura, Hiromi Tanimura, Tohru Ishikawa, (unknown), Kazuo Hattori, Nobuo Shimma, Hisafumi Yamada‐Okabe, Hideo Ishitsuka	8
7	Investigation of 5‐FU disposition after oral administration of capecitabine, a triple‐prodrug of 5‐FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5‐FU exposures in the tumour tissue between human and xenograft model 2001 ·Biopharmaceutics & Drug Disposition ·Yuko Tsukamoto, Yukio Kato, Masako Ura, Ikuo Horii, Tohru Ishikawa, Hideo Ishitsuka, Yuichi Sugiyama	17
8	A Physiologically Based Pharmacokinetic Analysis of Capecitabine, a Triple Prodrug of 5-FU, in Humans: The Mechanism for Tumor-Selective Accumulation of 5-FU 2001 ·Pharmaceutical Research ·Yuko Tsukamoto, Yukio Kato, Masako Ura, Ikuo Horii, Hideo Ishitsuka, Hiroyuki Kusuhara, (unknown)	65
9	The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, Capecitabine 2000 ·Bioorganic & Medicinal Chemistry ·Nobuo Shimma, Isao UMEDA, (unknown), (unknown), (unknown), Yasunori Kohchi, Masanori Miwa, Masako Ura, Noriaki Sawada, (unknown), (unknown), Ikuo Horii, Hideo Ishitsuka	107
10	Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue breakdown → 1998 ·European Journal of Cancer ·Masanori Miwa, Masako Ura, M Nishida, Noriaki Sawada, T Ishikawa, Kazushige Mori, Nobuo Shimma, Isao UMEDA, Hideo Ishitsuka	1039
11	Regression of increased left ventricular masses in elderly hypertensive patients on lisinopril as assessed by magnetic resonance imaging 1996 ·Academic Radiology ·Satoshi Handa, (unknown), Masako Ura, S. Yoshida, Ichiro Nishio	2
12	Selective inhibition of spontaneous pulmonary metastasis of lewis lung carcinoma by 5′‐deoxy‐5‐fluorouridine 1995 ·International Journal of Cancer ·Tohru Ishikawa, Masako Ura, (unknown), Yutaka Tanaka, Hideo Ishitsuka	17
13	Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5?-deoxy-5-fluorouridine 1993 ·Cancer Chemotherapy and Pharmacology ·Hiroyuki Eda, Kaori Fujimoto, Shinichi Watanabe, Masako Ura, Ayako Hino, Yutaka Tanaka, Kenji Wada, Hideo Ishitsuka	190
14	Responses of Cytosolic Free Calcium to ADP in Platelets of Spontaneously Hypertensive Rats 1990 ·American Journal of Hypertension ·Atsushi Baba, Kanji Fukuda, Takeshi Hano, (unknown), (unknown), Masako Ura, Yuichi Nakamura, Masato Kuchii, Ichiro Nishio, (unknown)	2
15	Effect of centrifugal force and catecholamines on glycosaminoglycans synthesis of vascular smooth muscle cells in culture 1990 ·Atherosclerosis ·Michiaki Hamada, (unknown), Ichiro Nishio, Masako Ura, (unknown), Takuzo Hano, Yoshiaki Masuyama	4
16	Enhanced DNA synthesis of cultured vascular smooth muscle cells from spontaneously hypertensive rats Difference of response to growth factor, intracellular free calcium concentration and DNA synthesizing cell cycle 1990 ·Atherosclerosis ·Masanori Hamada, Ichiro Nishio, (unknown), Kazuya Fukuda, (unknown), Masako Ura, Takuzo Hano, Masato Kuchii, Yoshiaki Masuyama	34
17	Role of substance P and neurotensin in the regulation of neurosecretion and vascular responsiveness in hypertension 1988 ·Journal of Hypertension ·Kazushi Tsuda, Hiroki Shima, Masako Ura, (unknown), Keizo Kimura, Ichiro Nishio, Yoshiaki Masuyama	4
18	Membrane fluidity of erythrocytes and its relevance to renin profile in essential hypertension. 1988 ·Japanese Circulation Journal ·Kazushi Tsuda, Seiko Tsuda, Yohsuke Minatogawa, Hideo Iwahashi, Hiroki Shima, Hiroyuki Yoshikawa, Masako Ura, (unknown), (unknown), Ichiro Nishio, Ryo Kido, Yoshiaki Masuyama	11
19	Protein kinase C-dependent and calmodulin-dependent regulation of neurotransmitter release and vascular responsiveness in spontaneously hypertensive rats 1988 ·Journal of Hypertension ·Kazushi Tsuda, Hiroki Shima, Masako Ura, (unknown), Keizo Kimura, Ichiro Nishio, Yoshiaki Masuyama	3
20	Intracellular free calcium concentration, Ca++ channel and calmodulin level in experimental hypertension in rats. 1987 ·Japanese Circulation Journal ·(unknown), Kazuya Fukuda, Masato Kuchii, Masako Ura, Hiroyuki Yoshikawa, Masanori Hamada, Takuzo Hano, Ichiro Nishio, Yoshiaki Masuyama	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact